argenx SE (NASDAQ:ARGX - Get Free Report) saw a significant decline in short interest in November. As of November 30th, there was short interest totalling 1,960,000 shares, a decline of 5.3% from the November 15th total of 2,070,000 shares. Based on an average daily volume of 260,400 shares, the days-to-cover ratio is currently 7.5 days.
Analysts Set New Price Targets
A number of equities analysts have recently issued reports on the company. Raymond James reissued a "strong-buy" rating and issued a $605.00 target price on shares of argenx in a report on Thursday, October 10th. Citigroup lifted their price objective on argenx from $512.00 to $635.00 and gave the company a "buy" rating in a report on Thursday, October 17th. Wedbush reaffirmed an "outperform" rating and issued a $655.00 target price on shares of argenx in a report on Tuesday, December 3rd. Oppenheimer reissued an "outperform" rating and set a $675.00 price target (up from $646.00) on shares of argenx in a report on Thursday, November 21st. Finally, Evercore ISI upped their price objective on shares of argenx from $675.00 to $706.00 and gave the stock an "outperform" rating in a research note on Thursday, November 21st. Three investment analysts have rated the stock with a hold rating, eighteen have given a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, the company has an average rating of "Moderate Buy" and a consensus price target of $635.11.
Check Out Our Latest Analysis on argenx
argenx Stock Up 0.9 %
NASDAQ ARGX traded up $5.69 during trading hours on Tuesday, hitting $638.33. The company's stock had a trading volume of 401,602 shares, compared to its average volume of 308,406. argenx has a twelve month low of $327.73 and a twelve month high of $644.97. The firm has a market capitalization of $38.53 billion, a P/E ratio of -725.38 and a beta of 0.59. The stock has a fifty day moving average of $583.23 and a 200 day moving average of $517.38.
argenx (NASDAQ:ARGX - Get Free Report) last announced its quarterly earnings results on Thursday, October 31st. The company reported $1.39 earnings per share for the quarter, beating analysts' consensus estimates of $0.10 by $1.29. argenx had a negative net margin of 2.11% and a negative return on equity of 1.45%. The business had revenue of $588.88 million for the quarter, compared to the consensus estimate of $543.29 million. During the same period last year, the company posted ($1.25) EPS. On average, analysts predict that argenx will post 2.2 earnings per share for the current year.
Hedge Funds Weigh In On argenx
A number of institutional investors and hedge funds have recently added to or reduced their stakes in ARGX. Blue Trust Inc. boosted its position in argenx by 620.0% during the 2nd quarter. Blue Trust Inc. now owns 72 shares of the company's stock worth $28,000 after acquiring an additional 62 shares during the last quarter. Point72 Hong Kong Ltd acquired a new position in argenx during the second quarter worth $76,000. Cromwell Holdings LLC grew its position in argenx by 73.3% in the third quarter. Cromwell Holdings LLC now owns 156 shares of the company's stock valued at $85,000 after purchasing an additional 66 shares in the last quarter. GAMMA Investing LLC increased its stake in argenx by 47.5% in the 3rd quarter. GAMMA Investing LLC now owns 174 shares of the company's stock valued at $94,000 after buying an additional 56 shares during the last quarter. Finally, Raymond James Trust N.A. bought a new stake in argenx during the 2nd quarter worth about $201,000. 60.32% of the stock is owned by institutional investors and hedge funds.
About argenx
(
Get Free Report)
argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren's syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.
Featured Articles
Before you consider argenx, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and argenx wasn't on the list.
While argenx currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
